A review of economic impact of targeted oral anticancer medications

Chan Shen, Chun Ru Chien, Daniel M. Geynisman, Fabrice Smieliauskas, Ya Chen T. Shih

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.

Original languageEnglish (US)
Pages (from-to)45-69
Number of pages25
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2014

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Pharmacology (medical)

Cite this